Helmholtz Zentrum München—；Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH);DEUTSCHES KREBSFORSCHUNGSZENTRUM;TECHNISCHE UNIVERSITÄT MÜNCHEN
The present invention relates to a binding molecule comprising at least three binding specificities, wherein (a) the first specificity is for a Hepatitis B virus (HBV) surface antigen selected from HBV small surface antigen, HBV medium surface antigen and HBV large surface antigen； (b) (i) the second and third specificity are for CD3 and CD28, respectively； or (ii) the second and third specificity are selected from specificities for CD16, CD56, NKp30, NKp46, 4-1BB and NKG2D； and (c) each binding specificity is provided by one or more binding sites, each binding site being independently provided by (i) a set of six complementarity determining regions (CDRs), wherein said set of six CDRs consists of a first set of three CDRs and a second set of three CDRs, wherein said first and said second set is each comprised in an immunoglobulin domain； or (ii) a set of three CDRs, wherein said set of three CDRs is comprised in an immunoglobulin domain.
